Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, mAbxience will be responsible for the manufacture of the active ingredient, developed by Biosidus as a biosimilar of Fabrazyme (agalsidase beta), which will be used for the treatment of Fabry disease.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Mabxience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2024